The Applicant has discovered a cytokine profile that can accurately distinguish between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having, or having symptoms of, inflammatory bowel disease (IBD). The profile of ulcerative colitis is increased IL-10 levels (compared with a reference IL-10 level, and decreased IL-23 levels (compared with a reference IL-23 level). The cytokine profile can be detected at a protein or genomic level, and is generally determined from a peripheral blood sample (i.e. a blood fraction such as serum, plasma, or blood cells such as peripheral blood mononuclear cells). Distinguishing between UC and CD in a subject with IBD allows a clinician prescribe a suitable therapeutic regime for the subject using a non-invasive blood test, and avoiding the need for scoping or tissue biopsy, which are undesirable for the subject. The cytokine profile can also be used to monitor a therapeutic regime for effectiveness.

The invention relates to body fluid test methods for the detection of cancer using a combination biomarker panel comprising at least one cytokine molecule and at least one cell free chromatin fragment.

Disclosed are a combined formulation kit for analyzing the phenotype and function of a CD1c.sup.+ dendritic cell subset and the use thereof, wherein the detection objects of the kit include CD1c, CD40, IL-6 and IL-10. The kit can be used to efficiently and quickly identify the phenotype of a CD1c.sup.+ dendritic cell subset in peripheral blood and analyze the function thereof, thereby ensuring accuracy and reducing the economic cost produced by detecting a large number of surface antigen molecules, and the detection method is also simple to implement.

The present invention relates to a marker for diagnosing colorectal cancer, a method for providing information required for the diagnosis of colorectal cancer by using same, and a method for providing information for monitoring the response to colorectal cancer therapy by using same.

The subject invention pertains to systems and methods diagnosing, monitoring and treating women for successful embryo implantation and establishment of pregnancy using peripheral blood cytokine profiling and administration of immune-modulators to establish an implantation-promoting microenvironment in the uterus.

Disclosed are compositions and methods to detect proteins associated with non-coeliac gluten sensitivity (NCGS). Such markers may be useful to allow individuals susceptible to NCGS to manage their food intake to avoid symptoms and further progression of disease.

Disclosed are methods for methods for quantitating and standardizing an anti-inflammatory response of a product and methods for determining the likelihood that a product would produce an anti-inflammatory effect in a subject when administered to the subject. Accordingly, disclosed herein are methods, compositions and kits for characterizing and evaluating the anti-inflammatory effect of products, particularly therapeutic biological products.

Disclosed are compositions and methods to detect proteins associated with non-coeliac gluten sensitivity (NCGS). Such markers may be useful to allow individuals susceptible to NCGS to manage their food intake to avoid symptoms and further progression of disease.

The present invention is directed to methods for using a plurality of particles comprising surfaces each independently comprising a capture moiety to isolate and characterize biomarkers (e.g., for obstructive sleep apnea).

Methods, systems, and kits for detection, diagnosis, monitoring, and/or treatment of viral infections such as represented by the COVID-19 disease are described. The methods, systems, and kits are capable of detection of salivary biomarkers which correlate with, and are indicative of, COVID-19 in a subject. Detection of the biomarkers in a saliva sample provides opportunities for a COVID-19 or other viral detection assay which is non-invasive, produces rapid results, and can be implemented in the field on a wide geographic basis for individualized screening or mass screenings for COVID-19 or other viral infections.